DEVIN RHYMAN: Open Payments
NPI 1881061422 · VISALIA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,021 in 92 payments from 26 companies in 2025. Trend: 2023 $2,156 · 2024 $1,796 · 2025 $2,021
Food & beverage: $2,021
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 9 | $266 |
| Novo Nordisk Inc | 14 | $249 |
| PFIZER INC. | 5 | $221 |
| Axsome Therapeutics, Inc. | 8 | $212 |
| ABBVIE INC. | 6 | $179 |
| Lilly USA, LLC | 12 | $130 |
| ABIOMED | 3 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| Merck Sharp & Dohme LLC | 3 | $66 |
Products named: RECORLEV, Auvelity, REXULTI, ZAVZPRET, Ozempic, QULIPTA, MOUNJARO, NURTEC ODT.
Industry payments across CA — which companies pay providers there.
